Holden William L, Juhaeri Juhaeri, Dai Wanju
Aventis Pharmaceuticals, Bridgewater, NJ, USA.
Pharmacoepidemiol Drug Saf. 2003 Oct-Nov;12(7):611-6. doi: 10.1002/pds.887.
This is the first part of a two-article series which will introduce the theory and practice of a proposed set of quantitative methods for benefit-risk analysis. Adjustments to number-needed-to-treat (NNT) analysis and a new method, minimum clinical efficacy (MCE) analysis are presented and critically discussed. The goal of these methods is to condense into a summary metric the benefit-risk profile of a product so that manufacturers, regulators, clinicians and patients can better understand and participate in risk management. A second article will present examples of these methods.
这是一个两篇文章系列的第一部分,该系列将介绍一套拟议的定量效益风险分析方法的理论与实践。文中介绍并批判性地讨论了对需治疗人数(NNT)分析的调整以及一种新方法——最小临床疗效(MCE)分析。这些方法的目标是将产品的效益风险概况浓缩为一个汇总指标,以便制造商、监管机构、临床医生和患者能够更好地理解并参与风险管理。第二篇文章将展示这些方法的实例。